Djokovic puts his quest for tennis history on the line as he searches for an alternative COVID-19 cure
In the wake of his denied entry into the 2022 Australian Open and a chance to break the Open Era Men’s Grand Slam title record, World No.1 Novak Djokovic has pinned his hopes on an alternative COVID-19 treatment instead of going through the usual vaccination route that has been globally accepted.
It has been revealed that the Serbian has an 80% stake in Danish biotech firm QuantBioRes, which is currently developing a peptide that would inhibit the coronavirus from infecting human cells. The company is expecting to launch clinical trials in the UK this summer.
The 2-week long saga, which happened in early January 2022 and caught the tennis world by storm, initially saw Djokovic granted a medical exemption from mandatory Covid-19 vaccination by Tennis Australia and the Department of Health of the Government of Victoria. However, it was swiftly overturned on the grounds of public interest and his visa was eventually cancelled, resulting in him being magnificently deported out of the country.
With his long-time rival, Rafael Nadal progressing in the tournament and on track to his 21st Grand Slam title, the World No.1’s quest to become the greatest tennis player in history has taken a massive step back. The immediate concern for Djokovic would be whether he can enter subsequent grand slams. The French Open, which is next in line, has announced that there will be no exemptions made regarding their vaccination rules.
For the fully story, read here